Additionally, the phase II WJOG @Be study reported encouraging results when testing atezolizumab with bevacizumab for advanced treatment-naive nonsquamous NSCLC with PD-L1 expression ≥50%. Here, CD274 is linked to non-small cell lung carcinoma.